The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Official Title: Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists: A Prospective, Observational, Phase IV Study (DELAY)
Study ID: NCT01366053
Brief Summary: This Phase IV observational trial is intended to identify patients who are failing GnRH agonist therapy as evidenced by a rising PSA and who have yet to initiate secondary manoeuvres involving antiandrogens. This group may include both non-metastatic as well as metastatic patients. The trial will determine if these patients will benefit from switching to Degarelix. It will assess the effect of Degarelix's direct mode of action on androgen levels and whether continuous use of Degarelix improves disease progression. As per the CUA Guidelines for the Management of CRPC, because the androgen receptor remains active in most patients who have developed castration resistant disease, it is recommended that ADT should be continued (LEVEL 3, GRADE C). Therefore, it is logical to continue patients on Degarelix throughout the castrate resistant period. This will allow for the gathering of data that is currently unknown within this setting, such as the effect of combined treatment with antiandrogens as well as chemotherapy and other castrate resistant treatments.
Detailed Description: This trial will include hormone sensitive prostate cancer patients switched to Degarelix therapy after failing on GnRH agonists but prior to use of secondary hormonal treatments such as antiandrogens. The purpose of this trial is to determine the effect of Degarelix's direct mode of action on androgen levels and whether continuous use of Degarelix improves disease progression. This is an open-label, multi-centre, Phase IV observational trial with s.c. injections of Degarelix one-month depot in patients with advanced prostate cancer. The visit frequency is once a month (28-day intervals), with eCRF data entry at every 4 months. All patients will be treated with a one-month starting dose followed by 23 monthly maintenance doses for a duration of 672 days. The primary endpoints will be evaluated after 24 treatment months. In total, 25 visits are scheduled for all patients.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Exdeo Clinical Research Inc., Abbotsford, British Columbia, Canada
Southern Interior Medical Research Inc., Kelowna, British Columbia, Canada
Andreou Research, Surrey, British Columbia, Canada
Dr. Steinhoff Clinical Research, Victoria, British Columbia, Canada
The Male/Female Health and Research Centre, Barrie, Ontario, Canada
Jonathan Giddens Medicine Professional Corporation, Brampton, Ontario, Canada
Brantford Urology Research, Brantford, Ontario, Canada
G. Kenneth Jansz Medicine Professional Corporation, Burlington, Ontario, Canada
Guelph Urology Associates, Guelph, Ontario, Canada
Mor Urology Inc., Newmarket, Ontario, Canada
Toronto Urology Clinical Study Group, North York, Ontario, Canada
The Fe/Male Health Centres, Oakville, Ontario, Canada
2150935 Ontario Inc., Owen Sound, Ontario, Canada
643094 Ontario Inc., Scarborough, Ontario, Canada
Stanley Flax Medical Professional Corporation, Toronto, Ontario, Canada
Urology South Shore Research Inc., Greenfield Park, Quebec, Canada
Urolaval, Laval, Quebec, Canada
Name: Richard Casey, M.D.
Affiliation: CMX Research
Role: PRINCIPAL_INVESTIGATOR
Name: Alvaro Morales, M.D.
Affiliation: Queens University
Role: PRINCIPAL_INVESTIGATOR